Evidence map›Paper›PMID 23197492›Full record

ArticleJournal of the National Cancer Institute2012

Nonsteroidal anti-inflammatory drug use, chronic liver disease, and hepatocellular carcinoma.

Vikrant V Sahasrabuddhe, Munira Z Gunja, Barry I Graubard, Britton Trabert, Lauren M Schwartz, Yikyung Park, Albert R Hollenbeck, Neal D Freedman, Katherine A McGlynn

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the National Cancer Institute, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 124 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
124citing papers in PubMed, 8 pooled it
11.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

124 citing papers in PubMed, 8 syntheses or guidelines pooled it, 228 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Guideline
  4. Pooled it
  5. Guideline
  6. Guideline
  7. Pooled it
  8. Pooled it
  9. Association between C-reactive protein, incident liver cancer, and chronic liver disease mortality in the Linxian Nutrition Intervention Trials: a nested case-control study.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2015
    Trial
  10. Trial
  11. Article
  12. Chemoprevention of hepatocellular carcinoma.Hepatology communications · 2025
    Review
  13. Article
  14. Review
  15. The Influence of Residential Segregation, Urbanicity, and Population Density on Hepatocellular Carcinoma Incidence among a Low Socioeconomic Population.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2025
    Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review

64 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Vikrant V SahasrabuddheDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, 6120 Executive Blvd, EPS 5032, Rockville, MD 20852, USA. vikrant.sahasrabuddhe@nih.gov
Munira Z Gunja
Barry I Graubard
Britton Trabert
Lauren M Schwartz
Yikyung Park
Albert R Hollenbeck
Neal D Freedman
Katherine A McGlynn
National Cancer Institute · USNational Institutes of Health · USDepartment of Health and Human Services · US

Funding

Prospective Studies of Diet and Cancer in the AARP CohortZIACP010196 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI SINHA, RASHMI · 2009 to 2025
$21.0M
Intramural NIH HHS Z99 CA999999
6 · The paper itself

Abstract

backgroundNonsteroidal anti-inflammatory drugs (NSAIDs) have been shown to reduce chronic inflammation and risk of many cancers, but their effect on risk of hepatocellular carcinoma (HCC) and death due to chronic liver disease (CLD) has not been investigated.

methodsWe analyzed prospective data on 300504 men and women aged 50 to 71 years in the National Institutes of Health-AARP Diet and Health Study cohort and linked self-reported aspirin and nonaspirin NSAID use with registry-confirmed diagnoses of HCC (n=250) and death due to CLD (n=428, excluding HCC). We calculated hazard rate ratios (RRs) and their two-sided 95% confidence intervals (CIs) using Cox proportional hazard regression models with adjustment for age, sex, race/ethnicity, cigarette smoking, alcohol consumption, diabetes, and body mass index. All tests of statistical significance were two-sided.

resultsAspirin users had statistically significant reduced risks of incidence of HCC (RR = 0.59; 95% CI = 0.45 to 0.77) and mortality due to CLD (RR = 0.55; 95% CI = 0.45 to 0.67) compared to those who did not use aspirin. In contrast, users of nonaspirin NSAIDs had a reduced risk of mortality due to CLD (RR = 0.74; 95% CI= 0.61 to 0.90) but did not have lower risk of incidence of HCC (RR = 1.08; 95% CI = 0.84 to 1.39) compared to those who did not use nonaspirin NSAIDs. The risk estimates did not vary in statistical significance by frequency (monthly, weekly, daily) of aspirin use, but the reduced risk of mortality due to CLD was statistically significant only among monthly users of nonaspirin NSAIDs compared to non-users.

conclusionsAspirin use was associated with reduced risk of developing HCC and of death due to CLD whereas nonaspirin NSAID use was only associated with reduced risk of death due to CLD.

Indexed as

AgedAnti-Inflammatory Agents, Non-SteroidalAspirinCarcinoma, HepatocellularChronic DiseaseComorbidityCyclooxygenase 1Cyclooxygenase 2Cyclooxygenase InhibitorsFemaleHumansIncidenceLiver DiseasesLiver NeoplasmsMaleMiddle AgedAnti-Inflammatory Agents, Non-SteroidalAspirinCyclooxygenase 1Cyclooxygenase 2Cyclooxygenase InhibitorsPTGS1 protein, humanPTGS2 protein, human

Identifiers

PMID23197492
PMCPMC3514167
OpenAlexW2098964407

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.